Clinical trials: Sickle Cell Anemia Crisis
Sickle Cell Disease, Sickle Cell Crisis
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg/kg/dose IV (<16yo max 15mg, >16yo max…
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis, Veno-occlusive Disease
- Trial name
- NCT06579703
- Testing
- Ketorolac
- Volunteers
- 102 people
- Sponsor
- Children's Blood and Cancer Center at Dell Children's Medical Center
Vaso Occlusive Crisis, Acute Chest Syndrome
Validation of a Predictive Score of Acute Chest Syndrome
Vaso-Occlusive Crisis (VOC), the most common manifestation of sickle cell disease (SCD), is the first cause of death, particularly when complicated by an acute chest syndrome (ACS).
- Trial name
- Presev2 (NCT03032055)
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Soutien aux Actions contre les Maladies du Globule Rouge
Sickle Cell Disease
Pilot Study on the Value of Bedside Pleuropulmonary Ultrasound in Patients With Sickle Cell Disease Presenting With Vaso-occlusive Crisis
Describe the proportion of patients with major sickle cell syndrome in vaso-occlusive crisis presenting at least one pleuropulmonary ultrasound abnormality during one of the ultrasounds performed at D0, between D2 and D5 during…
- Trial name
- DREPP (NCT06755385)
- Testing
- Pleuropulmonary ultrasound
- Volunteers
- 25 people
- Sponsor
- University Hospital, Grenoble
Sickle Cell Disease
Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients
Prospective phase IV interventional open label randomized controlled trial to assess safety and efficacy of glutamine in preventing vaso-occlusive crisis (VOC) episodes in sickle cell pediatrics and adolescents' patients
- Trial name
- Glu_SCD_Egy (NCT05371184)
- Testing
- L-Glutamine, Oral Powder for Reconstitution, Standard of care
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Sickle Cell Disease
Evaluation of Repeat Administration of Purified Poloxamer 188
The purpose of this study is to evaluate the safety of repeat administration of MST-188 during vaso-occlusive crisis of sickle cell disease.
- Trial name
- EPIC-E (NCT02449616)
- Testing
- MST-188
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- Mast Therapeutics, Inc.
Hemoglobin SC Disease
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes. Hemoglobin SCD (HbSC) is a form of SCD that is characterized by dense red blood cells.
- Trial name
- NCT00532883
- Testing
- Hydroxyurea, Magnesium Pidolate
- Where
- 19 sites in United States
- Volunteers
- 44 people
- Sponsor
- St. Jude Children's Research Hospital
Vaso-occlusive Crisis, Sickle Cell Anemia Crisis
Hyperbaric Oxygen Therapy in Sickle Cell Pain
Sickle cell anemia is a genetic blood disorder where red blood cells are abnormally shaped, crescent- or sickle-shaped, instead of the normal, round shape.
- Trial name
- HAVOC (NCT03412045)
- Testing
- hyperbaric oxygen therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Nebraska
Sickle Cell Disease, Vaso-occlusive Crisis
Steroid Treatment for Sickle Cell Pain Crisis
The painful episode is the most common problem experienced by children with sickle cell disease. Although various treatments are available during painful episodes, the medication most commonly given for pain is a pain medication…
- Trial name
- NCT00263562
- Testing
- Steroid arm
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Baylor College of Medicine
Sickle Cell Disease
A Study to Learn About Sickle Cell Disease In Adult Patients
The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in people with SCD who are on treatment that will change SCD and those not on such a treatment.
- Trial name
- NCT05407805
- Testing
- Electronic Diary
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Pfizer
Sickle Cell Disease
Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease
The goal of this pilot study is to improve emergency department (ED) pain management for adults with sickle cell disease. Sickle cell disease (SCD) is the most common genetic disorder in the United States, and occurs primarily…
- Trial name
- NCT02222246
- Testing
- Hydromorphone (Standardized, weight-based dosing), Morphine Sulfate (Standardized, weight-based dosing), Hydromorphone (Patient Specific dosing)
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- Duke University
Anemia, Sickle Cell, Pain
Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis
The purpose of this study is to determine if intranasal fentanyl can decrease the pain of patients with sickle cell disease who present to the pediatric emergency department with a vaso-occlusive crisis.
- Trial name
- NCT01482091
- Testing
- Fentanyl Citrate, Normal Saline
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Montefiore Medical Center
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease
Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises
This study aims to evaluate the use of virtual reality as an adjunct to standard care for patients with sickle cell disease experiencing vaso-occlusive crises.
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Acute Pain
- Trial name
- NCT06184126
- Testing
- Virtual Reality Headset and Hand-Held Controllers, Blindfolding and Noise Cancelling
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Anemia, Sickle Cell
A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients
Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis who are admitted to the hospital for treatment.
- Trial name
- NCT02672540
- Testing
- SANGUINATE 320 mg/kg, Normal Saline
- Where
- 4 sites in Colombia, Dominican Republic and 2 more
- Volunteers
- 34 people
- Sponsor
- Prolong Pharmaceuticals
Sickle Cell Disease
Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease
The primary objective of the proposed study is to determine the potential role of Ketamine as an analgesic agent in pediatric sickle cell disease patients with refractory symptoms in acute (VOC).
- Trial name
- KSickle (NCT02801292)
- Testing
- Ketamine
- Volunteers
- 20 people
- Sponsor
- Augusta University
Sickle Cell Disease, Vaso-occlusive Crisis
Outcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease
This study aims to assess the incidence and clinical outcomes of vaso-occlusive crises in pediatric patients with sickle cell disease. Data will be collected and analyzed to identify risk factors and related complications.
- Trial name
- NCT07200869
- Testing
- No intervention
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Assiut University
Sickle Cell Disease
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
The purpose of this study is to find objective biomarkers of vaso-occlusion (blood vessel blockage) in people with SCD. Using information from earlier studies and work being done, researchers have developed a strategy to image…
- Trial name
- NCT04925492
- Testing
- Positron Emission Tomography, Cu-64]-LLP2A
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Enrico Novelli
Sickle Cell Disease (SCD)
Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
The purpose of the CSEG101A2202 study was to characterize the Pharmacokinetic (PK) and Pharmacodynamic (PD) of SEG101/crizanlizumab and to evaluate the safety and efficacy of SEG101/crizanlizumab in sickle cell disease (SCD)…
- Trial name
- NCT03264989
- Testing
- crizanlizumab
- Where
- 12 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Sickle Cell Crisis
Transillumination Device for Peripheral Intravenous Placement in Patients With Sickle Cell Disease (PERFID)
The primary goal of this randomized, controlled, open-label study is to determine the efficacy of AccuveinV400 (a transillumination veins device) to facilitate peripheral intravenous (IVP) catheter placement during a…
- Trial name
- PERFID (NCT03477552)
- Testing
- Accuvein V400 device, Routine procedure
- Where
- 2 sites in France
- Volunteers
- 126 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sickle Cell Disease, Sickle Cell Crisis
A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises
Sickle cell disease (SCD) is the most common inherited blood disorder affecting 80,000 to 90,000 individuals in the United States.[10] There are 13,000 hospital admissions for a sickle cell crises, costing $448 million dollars…
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis, Vaso-Occlusive Crises
- Trial name
- NCT02698761
- Testing
- Comprehensive Care Plan
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Valley Anesthesiology Consultants
Sickle Cell Disease (SCD)
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
Sickle cell disease (SCD) is a genetic blood disorder. Crizanlizumab is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in patients with SCD aged 16 years and older.
- Trial name
- NCT04662931
- Testing
- crizanlizumab
- Where
- 7 sites in India
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals